Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C

Amanda Mocroft, Jurgen Rockstroh, Vincent Soriano, Ole Kirk, Jean Paul Viard, Saulius Caplinskas, Jacek Gasiorowski, Antonio Chiesi, Andrew N. Phillips, Jens D. Lundgren

Research output: Contribution to journalArticle

13 Citations (Scopus)


Uptake of hepatitis C (HCV) treatment in HIV-coinfected patients is not well described. Of 2356 HCV-seropositive patients, 180 (7.6%) started HCV treatment with interferon-based therapies. In multivariate Poisson-regression models, there was a 38% increase per year in the incidence of starting HCV treatment (95% CI 26-51%, p <0.0001); this increased from 3.9 per 1000 person-years follow-up (PYFU) before 1998 (95% CI 1.6-6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5-42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe.

Original languageEnglish
Pages (from-to)1092-1097
Number of pages6
JournalScandinavian Journal of Infectious Diseases
Issue number11-12
Publication statusPublished - Nov 2006
Externally publishedYes


ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this